Dr. Alexander Bondoc · Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models
Follow
Article1 min read·Published Aug 2021Older

Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Aug 2021 · 1 min read

In brief

In brief

This study identifies aggressive liver cancer domains (ALCDs) as critical genomic regions in chemoresistant hepatoblastoma and demonstrates that the JNK1/2-p53-PARP1 pathway activates oncogenic programs in these tumors. Using patient-derived xenograft models, researchers show that the FDA-approved PARP inhibitor olaparib significantly inhibits aggressive hepatoblastoma growth, offering a potential targeted therapy for treatment-resistant cases.

Written by the GCMD Library team from the article.

Alexander Bondoc

Background And Aims: Hepatoblastoma (HBL) is a devastating pediatric liver cancer with multiple treatment options, but it ultimately requires surgery for a cure. The most malicious form of HBL is a chemo-resistant aggressive tumor that is characterized by rapid growth, metastases, and poor response to treatment. Very little is known of the mechanisms of aggressive HBL, and recent focuses have been on developing alternative treatment strategies. In this study, we examined the role of human chromosomal regions, called aggressive liver cancer domains (ALCDs), in liver cancer and evaluated the mechanisms that activate ALCDs in aggressive HBL. Results: We found that ALCDs are critical regions of the human genome that are located on all human chromosomes, preferentially in intronic regions of the oncogenes and other cancer-associated genes. In aggressive HBL and in patients with Hepatocellular (HCC), JNK1/2 phosphorylates p53 at Ser6, which leads to the ph-S6-p53 interacting with and delivering the poly(adenosine diphosphate ribose) polymerase 1 (PARP1)/Ku70 complexes on the oncogenes containing ALCDs. The ph-S6-p53-PARP1 complexes open chromatin around ALCDs and activate multiple oncogenic pathways. We found that the inhibition of PARP1 in patient-derived xenografts (PDXs) from aggressive HBL by the Food and Drug Administration (FDA)-approved inhibitor olaparib (Ola) significantly inhibits tumor growth. Additionally, this is associated with the reduction of the ph-S6-p53/PARP1 com

Statements in this article

  1. Hepatoblastoma is a pediatric liver cancer that ultimately requires surgery for a cure.

    EstablishedBackground And Aims
  2. The most malicious form of hepatoblastoma is a chemo-resistant aggressive tumor characterized by rapid growth, metastases, and poor response to treatment.

    EstablishedBackground And Aims
  3. Aggressive liver cancer domains are located on all human chromosomes, preferentially in intronic regions of oncogenes and other cancer-associated genes.

    ResearchResults
  4. In aggressive hepatoblastoma and hepatocellular carcinoma, JNK1/2 phosphorylates p53 at Ser6.

    ResearchResults
  5. Phosphorylated S6-p53 interacts with and delivers PARP1/Ku70 complexes to oncogenes containing aggressive liver cancer domains.

    ResearchResults
  6. The ph-S6-p53-PARP1 complexes open chromatin around aggressive liver cancer domains and activate multiple oncogenic pathways.

    ResearchResults
  7. Inhibition of PARP1 in patient-derived xenografts from aggressive hepatoblastoma by olaparib significantly inhibits tumor growth.

    ResearchResults
  8. Olaparib treatment is associated with reduction of the ph-S6-p53/PARP1 complex.

    ResearchResults

Read it at the source ↗

Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.